What to expect in the Mineralys Therapeutics, Inc. interview process

Based on publicly available sources and company details, Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company founded in 2020 and headquartered in Radnor, Pennsylvania. Focused on developing targeted therapies—specifically its primary asset, lorundrostat—for hypertension and related cardiorenal disorders like chronic kidney disease and obstructive sleep apnea, the company operates with a lean footprint.

Headcount estimates generally range from around 50 to nearly 130 employees, reflecting a rapidly growing organization that went public via an IPO in 2023 and has raised $158 million across three funding rounds backed by investors such as Orbimed, RTW Investments, and RA Capital. Its workforce is distributed across the United States, Canada, and the United Kingdom.

Public data regarding internal workplace culture, management styles, day-to-day workloads, or return-to-office mandates is extremely limited. However, hiring data indicates that positions—such as a remote Territory Manager role posted with a salary range of $130,000 to $165,000—typically stay open for an average of 24 days. Additionally, immigration and visa data shows minimal historical reliance on H-1B labor petitions, with only a single approved petition noted in recent years.